Abstract
AHOD0031, a phase III trial assessing response-based therapy in intermediate-risk Hodgkin lymphoma, mandated central review of all radiation therapy (RT) and imaging records by QARC to maximize compliance with treatment and response evaluation guidelines. We report the impact of systematic RT data review on protocol compliance.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
